Skip to main content
KARD logo

KARD · Kardigan, Inc.

Track KARD — free
$12.68 +0.36 (+2.92%)
Market Cap
$1.15B
Shares
93.60M
Volume · Nov 19 538.43K Avg daily vol (3M) 603.96K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$12.32 Open$13.19 Day$12.25–13.51 Available close range$12.32–25.90 Avg vol 30d511K Short int5.7M · 6.1% of shares · 11.2d Short vol75% Last earningsNov 12, 2026 DataJun 2026–Nov 2026 Filing10-Q · Nov 12

The closing range uses available history since Jun 18, 2026; less than a full year is stored.

Latest documents

2026
Nov 18
Investor event
Danicamptiv six-month data due in Q2 of next year

Kardigan expects six-month Danicamptiv data in Q2 of next year, covering echocardiographic parameters and a directional change in peak VO2. Those correlations could confirm sizing for the 250-patient registrational study. Atasaguat registrational trial details are due in the first half of next year.

4 source passages
That's what we're going to show at the week 26 or the six-month endpoint in Q2 of next year. we'll have those echocardiographic parameters as well as the change in peak VO2 as a directional trend we're properly sized at 250 patient or subject phase three we'll share more data in the first half of next year on the Phase III trial Open the document at this passage
Nov 18
Investor event
Danicamptiv six-month data due in second quarter

Cardigan said six-month data for Danicamptiv in genetic cardiomyopathy comes in the second quarter, with peak VO2 correlations. Week 48 data for Atasaguat in Catalyst AV will confirm AVA and peak VO2, with registrational trial details in the first half of next year. About 80% of mild and moderate aortic stenosis patients show cardiac damage.

5 source passages
starting in the second quarter with Dan and Camtiv At week 26, at six months, and that is the Q2 top-line data So week 48 is going to give us the data we need to confirm AVA and peak VO2 we'll share more details on the registrational trial in the first half of next year What we found is that 80% of patients with mild and moderate aortic stenosis have evidence of cardiac damage. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Three late-stage programs advance with $591.4 million cash

Kardigan advanced three late-stage programs—Danicamtiv, Ataciguat and Tonlamarsen—and expects clinical data in 2027. It reported $591.4 million in cash, cash equivalents and investments and a $230.9 million nine-month net loss.

Net loss $58.57M Diluted EPS -$0.64
Read from the MD&A section
4 source passages
We have three late-stage programs, Danicamtiv, Ataciguat, and Tonlamarsen, in clinical development for indications for which no approved therapies currently exist. We expect to report clinical data from our three late-stage programs in 2027 As of September 30, 2026, we had cash, cash equivalents and investments of $591.4 million. Our net losses were $230.9 million and $135.6 million for the nine months ended September 30, 2026 and 2025, respectively. Open the document at this passage
Nov 12
Current report 8-K
Danicamtiv Cohort 2 enrollment completed with $591.4 million cash

Kardigan completed enrollment in Cohort 2 of the Phase 2b danicamtiv KINSHIP-DCM trial, with topline data expected in 2Q 2027; it also completed ataciguat KATALYST-AV Phase 2b enrollment, with data expected in 2H 2027. Cash was $591.4 million.

Financial results
4 source passages
Completing enrollment in the Phase 2b portion of our Phase 2b/3 adaptive KINSHIP-DCM trial is a significant milestone for danicamtiv and for people with genetic dilated cardiomyopathy. Enrollment is complete in Cohort 2 (patients with non-MYH7/TTN variants or a family history of DCM) of the Phase 2b portion of the KINSHIP-DCM clinical trial, and topline data is expected in the second quarter of 2027; the Phase 3 trial is now enrolling across both cohorts. Completed enrollment in Phase 2b ataciguat KATALYST-AV trial; Week 48 topline data expected in 2H 2027 Cash Position: Cash, cash equivalents and investments were $591.4 million as of September 30, 2026, compared to $335.5 million as of December 31, 2025. Open the document at this passage
Nov 6
Current report 8-K
KATALYST-AV enrollment completed; primary endpoint shifts to Week 48

Kardigan completed enrollment in its Phase 2b KATALYST-AV trial of ataciguat for aortic stenosis, moving primary endpoint assessment to Week 48 and topline data to 2H 2027.

Regulation FD disclosure
3 source passages
Kardigan®, Inc. (Nasdaq: KARD), a precision cardiovascular company, today announced enrollment completion in the Phase 2b KATALYST-AV trial of ataciguat in people with aortic stenosis (AS). The primary endpoint in KATALYST-AV of AVC will now be assessed at Week 48, together with additional analyses evaluating change in AVA, LV mass index, stroke volume index, and E/e′. Kardigan expects to provide an update on its Phase 3 development plans in the first half of 2027 and to report Week 48 topline data in the second half of 2027. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$78.89M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+578.3%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
6.1%
Latest settlement · 11.2 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Limited Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 50-day avg −16%
below
RSI (14) 39
neutral
MACD trend Negative
52-week position 0%
near low
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+26% holders QoQ · +37 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.08% of shares out · ▲ +7.4% MoM · 11.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
87 holders — 13F breadth
Squeeze score 66
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 75%
annualized · 1-yr
Max drawdown −52%
past year
ATR 10.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
3 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−16% Bearish
RSI (14)
39 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+26% holders QoQ · +37 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.08% of shares out · ▲ +7.4% MoM · 11.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
87 holders — 13F breadth
Price context
position in its available closing range
Range low $12 Now $12 · 0% Range high $26
vs 50-day avg -16%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash Position $591.4M as of September 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
KARD
Kardigan, Inc.
this stock
$1.15B — — — 6.1%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
87
% held
84.1%
Net QoQ
+21.5M sh
Top holder
HRTG GPE, LLC
Held Float
View
Held by Funds
Fund positions
73
View
Short & Settlement
Short Interest Rising
Shares short
5.7M
Days to cover
11.2d
Change
+391.2K sh
View
Short Volume
Short vol %
75%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
3.8K
Value
$54.3K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
41.8%
Week of
Oct 12, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 18, 2026
This year
11

Kardigan expects six-month Danicamptiv data in Q2 of next year, covering echocardiographic parameters and a directional change in peak VO2. Those correlations could confirm sizing for the 250-patient registrational study. Atasaguat registrational trial details are due in the first half of next year.

View
Earnings & Events
Webcasts
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Kardigan Reports Third Quarter 20…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
KARD -21.4% -4.1% — -12.8% —
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -17.5% +1.4% — -9.4% —
Key facts CIK 2123613 CUSIP 485925101 13F (30d) 86 filings 86 filers Visit website Investor relations